Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

OncoImmunology

Volumn 5, Issue 10, 2016, Pages

  McWilliams, Emily M ^a,b   Mele, Jennifer M ^b   Cheney, Carolyn ^b   Timmerman, Elizabeth A ^b   Fiazuddin, Faraz ^b   Strattan, Ethan J ^b   Mo, Xiaokui ^a   Byrd, John C ^b   Muthusamy, Natarajan ^b   Awan, Farrukh T ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Chronic lymphocytic leukemia; natural killer cells

Indexed keywords

AF 1330 SP; CD94 ANTIGEN; HLA E ANTIGEN; MAB 1257 SP; MONALIZUMAB; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2A; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CELL KILLING; CHROMIUM RELEASE ASSAY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; NATURAL KILLER CELL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84990913687     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1226720     Document Type: Article

References (32)

1. R.L.Siegel, K.D.Miller, A.Jemal. Cancer statistics, 2016. CA 2016; 66:7-30; PMID:26742998; http://dx.doi.org/10.3322/caac.21332
2. F.T.Awan, J.C.Byrd. New strategies in chronic lymphocytic leukemia:shifting treatment paradigms. Clin Cancer Res 2014; 20:5869-74; PMID:25294898; http://dx.doi.org/10.1158/1078-0432.CCR-14-1889
3. S.Palmer, C.A.Hanson, C.S.Zent, L.F.Porrata, B.Laplant, S.M.Geyer, S.N.Markovic, T.G.Call, D.A.Bowen, D.F.Jelinek et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008; 141:607-14; PMID:18384436; http://dx.doi.org/10.1111/j.1365-2141.2008.07070.x
4. C.Veuillen, T.Aurran-Schleinitz, R.Castellano, J.Rey, F.Mallet, F.Orlanducci, L.Pouyet, S.Just-Landi, D.Coso, V.Ivanov et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32:632-46; PMID:22318393; http://dx.doi.org/10.1007/s10875-011-9624-5
5. L.Arlettaz, J.Villard, C.de Rham, S.Degermann, B.Chapuis, B.Huard, E.Roosnek. Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR αβ lymphocytes. Eur J Immunol 2004; 34:3456-64; PMID:15517612; http://dx.doi.org/10.1002/eji.200425210
6. B.Jabri, J.M.Selby, H.Negulescu, L.Lee, A.I.Roberts, A.Beavis, M.Lopez-Botet, E.C.Ebert, R.J.Winchester. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 2002; 17:487-99; PMID:12387742; http://dx.doi.org/10.1016/S1074-7613(02)00427-2
7. B.Jabri, N.P.M.De Serre, C.Cellier, K.Evans, C.Gache, C.Carvalho, J.F.Mougenot, M.Allez et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000; 118:867-79; PMID:10784586; http://dx.doi.org/10.1016/S0016-5085(00)70173-9
8. J.A.Dubovsky, K.A.Beckwith, G.Natarajan, J.A.Woyach, S.Jaglowski, Y.Zhong, J.D.Hessler, T.M.Liu, B.Y.Chang, K.M.Larkin et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122:2539-49; PMID:23886836; http://dx.doi.org/10.1182/blood-2013-06-507947
9. V.M.Braud, D.S.Allan, C.A.O'Callaghan, K.Soderstrom, A.D'Andrea, G.S.Ogg, S.Lazetic, N.T.Young, J.I.Bell, J.H.Phillips et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9; PMID:9486650; http://dx.doi.org/10.1038/35869
10. F.Borrego, M.Ulbrecht, E.H.Weiss, J.E.Coligan, A.G.Brooks. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998; 187:813-8; PMID:9480992; http://dx.doi.org/10.1084/jem.187.5.813
11. N.Lee, M.Llano, M.Carretero, A.Ishitani, F.Navarro, M.Lopez-Botet, D.E.Geraghty. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998; 95:5199-204; PMID:9560253; http://dx.doi.org/10.1073/pnas.95.9.5199
12. M.Hallek, B.D.Cheson, D.Catovsky, F.Caligaris-Cappio, G.Dighiero, H.Döhner, P.Hillmen, M.J.Keating, E.Montserrat, K.R.Rai et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood 2008; 111:5446-56; PMID:18216293; http://dx.doi.org/10.1182/blood-2007-06-093906
13. H.B.Mann, D.R.Whitney. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist; 18(1):50-60; http://dx.doi.org/10.1214/aoms/1177730491
14. G.Verbeke, G.Molenberghs. Linear Mixed Models for Longitudinal Data. Springer-Verlag New York, 2000; 570:1; http://dx.doi.org/10.1007/978-1-4419-0300-6
15. J.Hsu. Multiple comparisons:theory and methods. CRC Press Boca Raton, FL, 1996; http://dx.doi.org/10.1007/978-1-4899-7180-7
16. L.Wieten, N.M.Mahaweni, C.E.M.Voorter, G.M.J.Bos, M.G.J.Tilanus. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens 2014; 84:523-35; PMID:25413103; http://dx.doi.org/10.1111/tan.12478
17. K.S.Gustafson, G.D.Ginder. Interferon-γ induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1α to a distinct interferon-γ-responsive element. J Biol Chem 1996; 271:20035-46; PMID:8702722; http://dx.doi.org/10.1074/jbc.271.33.20035
18. A.I.Marusina, D.-K.Kim, L.D.Lieto, F.Borrego, J.E.Coligan. GATA-3 is an important transcription factor for regulating human NKG2A gene expression. J Immunol 2005; 174:2152-9; PMID:15699146; http://dx.doi.org/10.4049/jimmunol.174.4.2152
19. H.-W.Ziegler, N.E.Kay, J.M.Zarling. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27:321-7; PMID:6169660; http://dx.doi.org/10.1002/ijc.2910270310
20. N.E.Kay, J.M.Zarling. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63:305-9; PMID:6607080
21. S.M.Jaglowski, L.Alinari, R.Lapalombella, N.Muthusamy, J.C.Byrd. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010; 116:3705-14; PMID:20610811; http://dx.doi.org/10.1182/blood-2010-04-001230
22. C.Veuillen, T.Aurran-Schleinitz, R.Castellano, J.Rey, F.Mallet, F.Orlanducci, L.Pouyet, S.Just-Landi, D.Coso, V.Ivanov et al. Primary B-CLL resistance to NK Cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32:632-46; PMID:22318393; http://dx.doi.org/10.1007/s10875-011-9624-5
23. J.R.Rodgers, R.G.Cook. MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 2005; 5:459-71; PMID:15928678; http://dx.doi.org/10.1038/nri1635
24. B.H.Koller, D.E.Geraghty, Y.Shimizu, R.DeMars, H.T.Orr. HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. J Immunol 1988; 141:897-904; PMID:3260916
25. M.Buschle, D.Campana, S.R.Carding, C.Richard, A.V.Hoffbrand, M.K.Brenner. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177:213-8; PMID:7678114; http://dx.doi.org/10.1084/jem.177.1.213
26. M.Carretero, G.Palmieri, M.Llano, V.Tullio, A.Santoni, D.E.Geraghty, M.López-Botet. Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A:evidence for receptor function in heterologous transfectants. Eur J Immunol 1998; 28:1280-91; PMID:9565368; http://dx.doi.org/10.1002/(SICI)1521-4141(199804)28:04%3c1280::AID-IMMU1280%3e3.0.CO;2-O
27. G.Palmieri, V.Tullio, A.Zingoni, M.Piccoli, L.Frati, M.Lopez-Botet, A.Santoni. CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J Immunol 1999; 162:7181-8; PMID:10358164
28. C.Zhang, J.Zhang, R.Sun, J.Feng, H.Wei, Z.Tian. Opposing effect of IFNγ and IFNα on expression of NKG2 receptors:Negative regulation of IFNγ on NK cells. Int Immuno Pharmacol 2005; 5:1057-67; PMID:15829421; http://dx.doi.org/10.1016/j.intimp.2005.02.003
29. S.Nguyen, N.Dhedin, J.-P.Vernant, M.Kuentz, A.A.Jijakli, N.Rouas-Freiss, E.D.Carosella, A.Boudifa, P.Debré, V.Vieillard. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations:immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005; 105:4135-42; PMID:15687235; http://dx.doi.org/10.1182/blood-2004-10-4113
30. V.Irani, A.J.Guy, D.Andrew, J.G.Beeson, P.A.Ramsland, J.S.Richards. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol 2015; 67:171-82; PMID:25900877; http://dx.doi.org/10.1016/j.molimm.2015.03.255
31. A.Gunturi, R.E.Berg, E.Crossley, S.Murray, J.Forman. The role of TCR stimulation and TGF-β in controlling the expression of CD94/NKG2A receptors on CD8 T cells. Eur J Immunol 2005; 35:766-75; PMID:15714583; http://dx.doi.org/10.1002/eji.200425735
32. L.Seymour, A.Tinker, H.Hirte, N.Wagtmann, P.Dodion. O3.2Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. Annals Oncol 2015; 26:ii3; http://dx.doi.org/10.1093/annonc/mdv081.2